AYURVEDIC MANAGEMENT OF DYSLIPIDEMIA W.S.R TO MEDO ROGA: A CLINICAL TRIAL by Vijay Chaudhary et al.
AYUSHDHARA            ISSN: 2393-9583 (P)/ 2393-9591 (O) 
 An International Journal of Research in AYUSH and Allied Systems 
AYUSHDHARA | January - February 2020 | Vol 7 | Issue 1  2537 
 
     
 
 
AYURVEDIC MANAGEMENT OF DYSLIPIDEMIA W.S.R TO MEDO ROGA: A CLINICAL TRIAL 
Vijay Chaudhary1*, Suraj Negi2, Minakshi3, Sameet Masand4 
*1Professor, 2Research Scholar, 3Senior lecturer, P.G.Department of Kaumarbhritya, R.G.G.P.G. Ayurveda 
College, Paprola, Himachal Pradesh, India.  
4Assistant Professor, P.G.Department of Rasashastra evum Bhaishajya Kalpana, V.Y.D.S. Ayurved 
Mahavidyalya, Khurja, Uttar Pradesh, India. 
 
KEYWORDS: Medoroga, 
Obesity, Dyslipidemia, 
Dashang Guggulu, Triphaladi 
Kwatha, Atorvastation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
Obesity is one of the most common disorders of present era giving rise 
many serious consequences. Excessive intake of food along with stress, 
lack of exercise, and excess of junk food, canned food, soft drinks, 
beverages, food containing excessive fat and calories leads to obesity and 
coronary artery disease. In the present study comparative efficacy of 
Ayurvedic formulation (Dashang gugglu with Triphaladi Kwatha) was 
evaluated in a clinical trial to a standard drug i.e., atorvastatin on patients 
of Medoroga and dyslipidemia. Total 30 patients of obesity and 
dyslipidemia were registered for the present study and were equally 
divided in two trial groups. Group I patients were administered with 
Dashang Guggulu with Triphaladi Kwatha whereas Group II patients were 
given atorvastatin as control group for a duration of 60 days. Patients 
were thoroughly assessed on various scientific parameters during 
complete trial period. The trial drugs showed promising results on 
dyslipidemia as well as on obesity (reduction of weight). Group I shows 
promising results in reducing body weight, BMI, skin fold thickness and 
clinical features however Group II i.e., control group proves to be much 
effective in improving deranged serum lipid levels. In Group I the mean 
score of serum cholesterol was 231.41mg/dl which was reduced to 
189.08mg/dl with 18.29% reduction. In Group II average value for serum 
cholesterol was 210.53mg/dl which was reduced to 162.92mg/dl with 
22.62% reduction. Group I patients shows 5.60% reduction in BMI while 
Group II patients shows 2.15% change which means Ayurveda 
formulation is much more effective than atrovastatin in reducing BMI 
however difference in two therapies was statistically insignificant. These 
results prove the efficacy of Ayurvedic formulation in the management 
of Medoroga. 
 
INTRODUCTION 
Obesity is recognized as a major health 
problem in both developed as well as developing 
countries. It has been considered as one of the 
major risk factors for many other chronic diseases 
like diabetes, coronary artery disease etc. Today’s 
erroneous life style is primarily responsible for 
increasing incidence of this disease in the society. 
Majority of the population in the society is now 
inclined towards junk food which contains lot of 
fats. Physical activity is decreasing day by day 
which results in fat storage leading to obesity and 
related disorders. Obesity was an uncommon 
disorder in the previous centauries. In 1997 WHO 
(World Health Organization) formally recognized 
obesity as a global epidemic. In year 2008 WHO 
claimed 1.5 billion adults of 20 and older were 
overweight and of those 200 million men and 300 
million women were obese. Incidence of obesity in 
India is also rising with morbid obesity affecting 5% 
of countries population. In Ayurveda, Medoroga[1] 
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has been described in different texts in an elaborate 
manner covering its etiology, clinical features, 
complications, prognosis and management [2]. 
Acharya Charaka has described this clinical 
condition as one among the Ashtanindita purusha[3] 
(eight despicable persons). While Acharya Sushruta 
considers Sthoola[4] as Sadatura because Sthaulya is 
making the victim prone for so many other diseases. 
The Ayurvedic fundamental principle of Samanya 
and Visesha[5-6] is very essential for the 
understanding the state of health and diseases and 
the same can be applied for management of 
Medoroga. Most of the drugs used in modern era to 
manage obesity are associated with serious 
untoward effects and when these medicines are 
withdrawn a profound rebound weight gain is 
observed. Considering these facts, medical 
fraternity is always looking for safe and effective 
therapy for managing this notorious disease. Many 
studies were conducted in obesity like effect of 
Gomutra and Haritaki in controlling Sthaulya etc., 
considering all these studies and facts, the two 
compound herbal formulations have been selected 
for the present study on the basis of textual 
indications and clinical experience. Dashang 
Guggulu is one of the important Guggulu 
preparation used for Medoroga (obesity)[7]. As per 
Bhavprakasha, Dashanga Guggulu act 
therapeutically on Kapha and Medovikara. It also 
works in Amajvikara like Amavata also[8]. Triphala 
is used as Anupana with Dashang Guggulu as it is 
Ruksha, Agnideepak and Kaphanashak, so it is 
helpful in Medoroga.  
MATERIALS AND METHODS 
Selection of the Patients 
 A total of 30 patients were selected from the 
present study from O.P.D. and I.P.D. of Kayachikitsa 
department of R.G.G.P.G. Ayurvedic College 
Hospital, Paprola irrespective of their gender, caste 
and socio economic status etc. 
Criteria for Diagnosis 
1. Subjective Criteria- Classical signs and 
symptoms of Medoroga mentioned in 
Ayurvedic and modern texts. Table No. 1 
2. Objective Criteria Table no. 2 
Inclusion Criteria 
1. Patients willing to participate in the trial 
2. Age between 18 – 70 years. 
3. Only uncomplicated cases of Medoroga. 
4. Body mass Index (BMI)  > 25 
5. Deranged lipid profile 
S. Cholesterol  > 200 mg/ dl 
STG   >150 mg/dl 
LDL   > 100 mg/dl 
VLDL   > 40 mg/dl 
HDL   < 40 mg/dl 
Exclusion Criteria 
1. Patients not willing for the trial. 
2. All Medo Rogi presenting with complication 
like Prameha Pidika. 
3. Drug induced obesity. 
4. Obesity due to endocrine disorders. 
Laboratory Investigations - Hb gm %, TLC, DLC, 
ESR, FBS, Blood urea, Serum creatinine, SGOT, 
SGPT, Urine - Routine and microscopic 
Method of study 
Trial Group - Total 30 patients of Medoroga were 
selected for the present clinical study, they were 
randomly divided and managed into following two 
groups: 
1. Trial group: Total 15 patients were registered 
in trial group and out of them 3 patients 
discontinued the treatment and only 12 patients 
completed the study. The selected patients were 
given the trial drugs i.e., Dashang Guggul in the 
dose of 1.5g thrice a day and Triphaladi Kwatha 
in the dose of 50ml twice a day after meals. 
2. Control group: Total 15 patients were 
registered in control group and out of them 2 
patients discontinued the treatment and only 13 
patients completed the study. These patients 
were given tablet atorvastatin 10mg once a day.  
Duration of trial: Duration of trial was 60 days 
Patients were advised to visit for follow-up 
after every 15 days or as per requirement. Patients 
were explained the possible benefits of trial and 
strictly advised to not to discontinue the trial drug 
till the trial was over. They were advised not to take 
any medications during the trial period. Patients 
were advised to crush the pills of Dashang Guggulu 
before swallowing. Patients were told to follow the 
Pathya- Apathya, Ahara and Vihara according to 
Ayurvedic principles. They were advised to take 
plenty of green leafy vegetable and to avoid high 
calorie food and overall assessment was done by 
grading method. (Table no. 3) 
RESULTS  
All registered patients were assessed 
thoroughly after every 15 days for the effect of 
therapy on the basis of various subjective and 
objective criteria. Biochemical tests were also 
performed before starting and after completion of 
trial. Effects of therapy on various subjective and 
objective parameters are shown in Table No.4, 
Table No. 5, Table No. 6 and Table No.7. The overall 
effect of two trial drugs was evaluated on the basis 
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of various subjective and objective criteria selected 
for assessment of results. The patients were 
categorized into markedly improved, moderately 
improved, mildly improved and unchanged 
according to assessment criteria. (Table No.8) 
DISCUSSION 
The main improvement in symptoms i.e., 
Kshudra Shwasa, Pipasa Atiyoga, Swedabadha, 
Sandhi Shool, Daurgandhya, Daurbalya, Kshudha 
Atimatra, Chala Sphika Udara Stanam, Javoprodha in 
trial group was 51.19% and in control group it was 
17.35%. The improvement was highly significant 
(p<0.001) on Daurbalya and Sandhi Shool whereas 
in rest of symptoms i.e. Kshudra Shwasa, Pipasa 
Atiyoga, Swedabadha, Daurgandh, Kshudha 
Atimatra, Chala Sphika Udara Stanam, Javoprodha, 
effect of therapy was statistically significant 
(p<0.05) in trial group. In control group 
improvement was insignificant (p>0.05) on all the 
symptoms except on Daurbalya. Inter group 
difference on Kshudra Shwasa, Pipasa Atiyoga, 
Swedabadha, Sandhi Shool, and Daurgandhya was 
significant (p<0.05) and on rest of symptoms i.e. 
Daurbalya, Kshudha Atimatra, Chala Sphika Udara 
Stanam, Javoprodha, it was insignificant (p>0.05) 
Reduction in BMI in trial group was 5.60%. 
In control group it was 2.15%. Dashang Guggulu 
with Triphaladi Kwatha proved more effective in 
reducing BMI than control group drug i.e. 
atorvastatin however difference in two therapies 
was statistically insignificant (p>0.05). 
In trial group the mean score of serum 
cholesterol was 231.41mg/dl which was reduced to 
189.08mg/dl with 18.29% reduction. In control 
group average value for serum cholesterol was 
210.53mg/dl which was reduced to 162.92mg/dl 
with 22.62% reduction. Therapy given in control 
group i.e., Atorvastatin proved more effective in 
reducing S. Cholesterol. Difference in the effect of 
both the therapies was statistically significant 
(p<0.05). In trial group average value for serum 
triglyceride was 191.66mg/dl which was reduced to 
146.00mg/dl with 23.82% reduction. In control 
group average value for serum triglyceride was 
199.38mg/dl which was reduced to 127.77mg/dl 
with 35.92% reduction. Difference in the effect of 
both the therapies was significant (p<0.05). In trial 
group average value for serum LDL was 
148.50mg/dl which was reduced to 120.75mg/dl 
with 18.69% reduction. In control group average 
value for serum LDL was 174.77mg/dl which was 
reduced to 109.61mg/dl with 37.28% reduction. 
Difference in the effect of both the therapies was 
insignificant (p>0.05). In trial group average value 
for serum VLDL was 37.75mg/dl which was 
reduced to 29.33mg/dl with 22.29% reduction. In 
control group average value for serum VLDL was 
40.69mg/dl which was reduced to 26.69mg/dl with 
34.40% reduction. Difference in the effect of both 
the therapies was insignificant (p>0.05). In trial 
group the average value for serum HDL was 
45.17mg/dl which was increased to 48mg/dl with 
11.77% increase. In control group average value for 
serum HDL was 30.53mg/dl which was increased to 
40.38mg/dl with 32.26% increase. Difference in the 
effect of both the therapies was insignificant 
(p>0.05). 
Overall effect of therapy showed that out of 
12 patients in trial group 16.66% patients (02) 
showed marked improvement, 58.33% patients (7) 
were moderately improved and 25% patients (03) 
were mildly improved. In control group out of 13 
patients 07.69% (01) showed marked 
improvement, 15.38% patients (2) showed 
moderate improvement and 76.92% patients (10) 
were mildly improved. Most of the routine 
haematological and biochemical investigations 
remained within normal limits in both the groups 
before and after the therapy. 
The components of Dashang Guggulu 
[Purified Guggulu (Commiphora mukul), Haritaki 
(Terminalia chebula), Bibhitaki (Terminalia 
bellirica), Amalaki (Emblica officinalis), Pippali 
(Piper longum), Marich (Piper nigrum), Sunthi 
(Zingiber officinale), Chitrakmool (Plumbago 
zeylanica), Musta (Cyperus rotundus) and Vidang 
(Embelia ribes)] with Triphaladi Kwatha [Amla 
(Emblica officinalis), Haritaki (Terminalia chebula) 
and Vibhitaki (Terminalia bellirica)] are Deepan, 
Pachan, Kapha – Vatahara and Srotoshodhak as 
most of the drugs have Katu Tikta Rasa, Laghu, 
Ruksha, Tikshana, Guna, Ushana, Virya and Katu 
Vipaka so effectively interrupt the Samprapti of 
Medo Roga at various levels. 
Guggulu is responsible for reducing fat, 
indicated for healing bone fracture to inflammation, 
arthritis, atherosclerosis, obesity, and 
hyperlipidemia[9]. Guggulipid is a standardized 
extract prepared from the oleogum resin (gum 
resin) of Commiphora mukul, commonly known as 
Guggul belonging to the family Burseraceae, is 
indigenous to India and is also found in Bangladesh 
and Pakistan. It grows wild in the semi-arid states 
of Rajasthan, Gujarat, and Karnataka in India. As 
afore mentioned, GL has been safely used for 
thousands of years in the Indian Ayurvedic 
medicine for the treatment of different ailments, 
including lipid disorders, rheumatoid arthritis, 
ulcers, osteoarthritis, bone fractures, epilepsy, and 
obesity[10,11]. In 1986, GL was granted approval in 
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India for marketing as a lipid lowering drug[12]. 
Several products of standardized formulations of 
Commiphora mukul are already in human use as 
cholesterol-lowering agents. The Z- and E-forms of 
guggulsterone (Gug, 4, 17(20)-pregnadie-3, 16-
dione) have been identified as major active 
components of GL[10,13]. GL and its active component 
z-Gug have been used in many clinical trials that 
focused on its cholesterol-lowering effect. 
Commiphora mukul has been clinically proven to 
reduce the levels of harmful serum lipids in the 
blood stream. The active ingredients responsible for 
the maintenance of healthy cholesterol levels are 
the guggulsterones, specifically guggulsterone E and 
guggulsterone-Z [14,15]. 
The hypolipidemic activity of Guggulu could 
be attributed to the following possible mechanisms 
includes: [16] 
 Inhibition of cholesterol biosynthesis 
 Enhancing the rate of excretion of cholesterol 
 Promoting rapid degradation of cholesterol 
 Thyroid stimulation  
 Alteration of biogenic amines, High-affinity 
binding and anion exchange.  
The first three mechanisms, inhibition of 
cholesterol biosynthesis, enhancing the rate of 
excretion of cholesterol and promoting rapid 
degradation of cholesterol are related in that the 
end result is the elimination of cholesterol. Guggulu 
compounds are antagonist ligands for bile acid 
receptor called farnesoid X receptor (FXR), which is 
an important regulator of cholesterol homeostasis. 
It is likely that this effect accounts for the 
hypolipidemic activity of these phytosterols. 
Guggulsterone has the capability of inhibiting 
oxidative modification of LDL. While Guggulsterone 
E (GSE) or Z (GSZ) had no effect on FXR activity per 
se, both compounds statistically and dose 
dependently inhibited FXR activation by 
chenodeoxycholic acid, the most potent of the bile 
acids activating FXR. This may imply that 
guggulsterones enhance conversion of cholesterol 
into bile acids which could be excreted in the feces 
lowering the liver and body cholesterol level[17, 18]. 
Other drugs such as Triphala,[19] Pippali,[20] 
Shunthi,[21] Musta,[22] Chitraka,[23] and Vidanga[24] 
have also proven lipid lowering activity. Thus, the 
whole composition exhibited antihyperlipidemic 
effect.  
CONCLUSION 
The trial drugs showed promising results on 
obesity as well as on dyslipidemia. Body weight, 
BMI and serum lipids were also reduced 
significantly. Trial drugs i.e. Dashang Guggulu with 
Triphaladi Kwatha were found more effective in 
reducing body weight, BMI, skin fold thickness and 
clinical features however modern drug i.e. 
atorvastatin proved more effective in improving 
deranged serum lipid levels. Trial drugs have no 
untoward effects so can be used for a long duration. 
Thus it can be concluded that Dashang Guggulu with 
Triphaladi Kwatha have beneficial effect in patients 
of Medoroga and dyslipidemia but as the present 
study has been conducted on small sample size 
further multi centre and double blind studies on 
larger samples size needs to be done to confirm the 
effectiveness and safety of the drug. 
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Table 1: Subjective criteria were given grades according to severity of symptoms. 
S. no. Symptom Grading 
1. Kshudra Shawasa 
(Shortness of 
breath) 
No shortness of breath - 0 
Slight shortness of breath after hard physical work – 1 
 Shortness of breath after mild physical exercise - 2  
Shortness of breath even at rest - 3 
2. Sandhi Shoola 
(Pain in joints) 
No pain - 0 
Mild pain of low intensity causing no disturbance in routine work - 1 
Moderate pain hampering daily routine work  - 2 
Severe pain causing definite interruption in routine work -3 
3. Pipasa Atiyoga 
(Excessive thirst) 
< 1.5 Lit./ day of fluid - 0 
1.5 – 2 Lit./ day of fluid - 1 
2 – 3 Lit./ day of fluid - 2 
>3 Lit./ day of fluid – 3 
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4. Kshuda Atimatra 
(Excessive hunger) 
< 2 chapattis / meal – 0 
2 – 4 chapattis/ meal - 1 
4 – 6 chapattis/ meal - 2 
>6 chapattis/ meal - 3 
5. Javaparodha 
(Lassitude) 
 
Fully active – 0 
Hesitate to start work but once started, complete it - 1 
Start but does not complete - 2 
Doesn’t have drive, work under compulsion - 3 
6. Swedabadha 
(Excessive 
sweating) 
Normal perspiration – 0 
Mild perspiration after doing exertion - 1 
Heavy perspiration after doing little exertion - 2 
Perspiration without exertion – 3 
7. Nidradhikya 
(Excessive sleep) 
6 – 8 hrs/ day sleep – 0 
8 – 10 hrs/ day sleep - 1 
10 – 12 hrs/ day sleep - 2 
12 – 14 hrs/ day sleep – 3 
8. Chal Sphik Udra 
Stanan (Movement 
of body parts) 
Absence of movements – 0 
Little movement after fast activity - 1 
Movements after mild activity - 2 
Movements even on changing posture – 3 
9. Daurbalya 
(Weakness) 
No tiredness – 0 
Mild fatigue after doing work - 1 
Tired after doing work - 2 
Works with great difficulty – 3 
10. Daurgandhya (Bad 
odour) 
Absence of odour – 0 
Occasional bad odour - 1 
Persistent bad odour - 2 
Persistent bad odour intolerable to patient – 3 
Table 2: Objective criteria were given grades according to normal standards 
S.no. Criteria  
1.  Raised Body height- weight Ratio: BMI = Weight (kg)/Height(M)2 > 25 
2.  Body weight  Reduction of >4 kg of body weight. 
 Reduction of 2 – 4 kg of weight. 
 Reduction of 1 – 2 kg of weight 
3.  Lipid profile S. Cholesterol > 200 mg/dl 
S. Triglycerides > 160 mg/dl 
S. LDL > 160 mg/dl 
S. VLDL > 30 mg/dl 
S. HDL < 30 mg/dl 
Table 3: Overall assessment criteria 
S. no. Improvement criteria Grading 
1.   >60% Reduction in subjective symptoms. 
 Reduction of >4 kg of body weight. 
 Reduction of > 2 grades of BMI 
 More than30% reduction in two or more than two factors out of S. 
Markedly 
improved 
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Cholesterol, triglycerides, LDL, VLDL. 
 More than30% elevation in HDL. 
2.   > 30% Reduction in subjective symptoms. 
 Reduction of 2 – 4 kg of weight. 
 Reduction of one grade in BMI. 
 15-30% reduction in two or more than two factors out of S. 
Cholesterol, Triglycerides, LDL, VLDL. 
 15-30% elevation in HDL. 
Moderately 
improved 
3.   < 30% Reduction in subjective symptoms 
- Reduction of 1 – 2 kg of weight 
- Reduction of one grade in BMI. 
- Upto 15% reduction in one factor out of S. Cholesterol, 
triglycerides, LDL, VLDL 
- Upto 15% elevation in HDL. 
Mildly 
improved 
 
Table 4: Comparative effect of Dashang Guggulu with Triphaladi Kwatha and Atorvastatin on clinical 
features 
Clinical 
features 
Trial group Control Group I v/s 
II  
t 
 
P Mean score % age  
Reduction 
SD± T Mean score % age  
Reduction 
SD± T 
BT AT BT AT 
Kshudra 
Shwasa 
1.67 1.08 35.0 0.66 3.02 1.67 1.50 15.0 0.38 1.48 2.42 <0.05 
Pippasa Ati  
Yoga 
1.33 0.33 75.0 0.63 3.87 1.60 1.20 25.0 0.55 1.63 2.98 <0.05 
Swedabadha  1.09 0.45 58.33 0.50 4.18 1.50 1.25 16.66 0.46 1.53 2.26 <0.05 
Nidradhikya 1.14 0.42 62.5 0.48 3.87 1.42 1.14 20.0 0.49 1.55 1.81 >0.05 
Daurbalya 1.83 0.91 50.0 0.51 6.16 1.50 1.16 22.22 0.49 2.34 1.12 >0.05 
Kshudha 
Atimatra 
2.18 1.36 34.78 0.60 4.50 1.73 1.45 15.78 0.47 1.94 0.46 >0.05 
Chal Sphik 
Udar Stan 
1.63 1.00 38.88 0.50 4.18 1.58 1.33 15.78 0.45 1.91 1.44 >0.05 
Sandhi Shool 1.60 0.70 56.25 0.31 9.00 1.83 1.50 18.18 0.52 1.16 2.58 <0.05 
Javuprodha 1.54 0.90 41.17 0.50 4.18 1.54 1.27 17.64 0.47 1.93 1.14 >0.05 
Daurgandhya 1.11 0.44 60.00 0.50 0.40 1.30 1.00 23.07 0.48 1.96 3.29 <0.05 
Table 5: Comparative effect of Dashang Guggulu with Triphaladi Kwatha and Atorvastatin on body 
weight 
Criteria Trial group Control Group  
I vs II 
t 
 
P Body weight Mean 
weight 
% age 
reduction  
SD T Mean weight % age 
reduction 
SD T 
BT AT BT AT 
Weight (kg) 80.0 75.66 5.42 1.30 11.52 78.08 76.61 0.88 1.05 5.02 0.20 >0.05 
Table 6: Comparative effect of Dashang Guggulu with Triphaladi Kwatha and atorvastatin on BMI 
Criteria Trial group Control Group   
Mean value %age 
reduction 
SD T Mean value % age 
reduction 
SD t I v/s II 
t 
P 
BT AT BT AT 
BMI 31.73 29.27 5.60 0.48 13.29 31.53 30.80 2.15 0.39 6.59 0.48 >0.05 
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Table 7: Comparative effect of Dashang Guggulu with Triphaladi Kwatha and atorvastatin on Lipid 
profile 
 
 Variable 
Trial group Control Group  
I vs 
II t 
 
P Mean value % age 
change 
SD T Mean value %age 
change 
SD T 
BT AT BT AT 
S. cholesterol 231.41 189.1 18.29 17.4 8.4 210.5 162.9 22.62 26.5 6.49 2.33 <0.05 
S. Triglyceride 191.6 146.0 23.82 33.9 4.6 199.4 127.8 35.92 19.8 13.0 2.96 <0.05 
S. LDL 148.5 120.7 18.69 19.5 4.9 174.8 109.6 37.28 22.6 10.4 1.06 >0.05 
S. HDL 45.2 48.0 11.77 6.44 2.5 30.5 40.38 32.26 6.9 5.12 1.97 >0.05 
S. VLDL 37.7 29.3 22.29 07.2 4.0 40.7 26.7 34.40 5.4 9.37 1.96 >0.05 
Table 8: Overall effect of therapy in trial group and control group 
Result Trial Group Control Group Total 
No. of patients % age No. of patients % age No. of patients % age 
Markedly improved 02 16.66 01 07.69 03 12.17 
Moderately improved 07 58.33 02 15.38 09 36.85 
Mildly improved 03 25.00 10 76.92 13 50.96 
No improvement 00 00.00 00 00.00 00 00.00 
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